导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.76% | 1331/4773 |
| 近一周 | -1.94% | 925/5462 |
| 近一月 | 1.14% | 426/5421 |
| 近一季 | 1.05% | 585/5209 |
| 近半年 | -3.88% | 2348/4920 |
| 近一年 | 4.31% | 1747/4366 |
| 近两年 | 25.90% | 2457/2954 |
| 近三年 | 19.44% | 1488/2253 |
| 成立以来 | 63.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.08% 590/4961 |
-10.13% 4052/5312 |
- - |
- - |
| 2025 | 3.33% 3132/4813 |
-2.70% 2957/3635 |
2.50% 1531/4076 |
2.37% 3800/4524 |
1.21% 1471/4813 |
| 2024 | 16.79% 765/3463 |
8.00% 207/2808 |
2.23% 370/3014 |
8.25% 2758/3129 |
-2.29% 2029/3463 |
| 2023 | 5.03% 203/2656 |
4.80% 869/2280 |
0.81% 272/2385 |
3.89% 167/2515 |
-4.31% 955/2655 |
| 2022 | -1.42% 47/2207 |
1.78% 91/1919 |
-1.12% 1675/2016 |
-2.18% 31/2113 |
0.13% 1538/2208 |
| 2021 | 18.19% 215/1822 |
4.83% 134/1255 |
9.06% 587/1330 |
4.63% 330/1466 |
-1.20% 1328/1822 |
| 2020 | - - |
- - |
- - |
- - |
3.63% 898/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证红利ETF联接发起式A VS. 长安沪深300非周期A(740101) |